Showing results (491-500 of 661) with videos related to
Sort By:
Pageof 67
Nature Cancer|July 21, 2026
Dalpiciclib plus endocrine therapy in women with HR+/HER2- advanced breast cancer and visceral crisis: a multicenter, nonrandomized, phase 2 DARVIN trialHongnan Mo, Yuee Teng, Li Cai, et al.Nature Cancer|September 12, 2026
MMSDH facilitates ACSL4 propionylation to counteract ferroptosis upon hypoxia and impairs PDAC chemotherapy efficacyPeixiang Zheng, Yanni Lin, Meiyin Zhang, et al.Nature Cancer|September 15, 2026
Circulating tumor DNA-guided de-escalation or escalation of adjuvant therapy in high-risk stage II and stage III colon cancer: the phase 2 PEGASUS trialSilvia Marsoni, Clara Montagut, Filippo Pietrantonio, et al.Nature Cancer|September 22, 2022
Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockadeBaolin Liu, Yuanyuan Zhang, Dongfang Wang, et al.Nature Cancer|September 22, 2022
Artificial intelligence in histopathology: enhancing cancer research and clinical oncologyArtem Shmatko, Narmin Ghaffari Laleh, Moritz Gerstung, et al.Nature Cancer|October 27, 2022
Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signalingIdo Yofe, Tomer Landsberger, Adam Yalin, et al.Nature Cancer|October 17, 2022
A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genesJoshua J Gruber, Anosheh Afghahi, Kirsten Timms, et al.Nature Cancer|February 5, 2025
FLASH radiation reprograms lipid metabolism and macrophage immunity and sensitizes medulloblastoma to CAR-T cell therapyHaiwei Ni, Zachary J Reitman, Wei Zou, et al.Nature Cancer|January 9, 2025
Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinomaTejas Jammihal, Renee Maria Saliby, Chris Labaki, et al.Nature Cancer|January 13, 2025
ERα dysfunction caused by ESR1 mutations and therapeutic pressure promotes lineage plasticity in ER+ breast cancerJackson Liang, Xiaosai Yao, Patrick Aouad, et al.Pageof 67